The anti-Corona drug `Pfizer` will be available to more than half of the world's population... in a bold step that may turn the page of the epidemic that changed the world

Weather of Arabia - Pfizer Pharmaceutical Industries has signed an agreement with a United Nations-backed group to allow the manufacture of an experimental Covid-19 drug, and the company will grant a license to the anti-viral drug to the Geneva-based Drug Patent Pool, which will allow other pharmaceutical companies to produce the drug for use in 95 countries.

A move that could make treatment available to more than half of the world's population, health officials have said, the fact that the deal was struck, could help end the epidemic faster.

Other drug companies will be able to begin production of the anti-corona drug within months, and under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries and will waive sales royalties in all countries covered by the agreement, as long as the coronavirus remains a public health emergency.

The anti-coronavirus drug from "Merck" and "Pfizer"

Since the pandemic swept the world last year, researchers have raced to develop a drug to treat COVID-19 that can be taken at home easily to relieve symptoms, speed recovery and keep people away from hospital. Currently, most COVID-19 treatments must be given intravenously or intravenously. injection.

And in March, Pfizer, which together with the German pharmaceutical company Biontech, developed the first vaccine against Covid-19, began an early stage of clinical trials to test a new antiviral treatment to counteract Covid-19, the drug Paxlovid.

Earlier this month, Pfizer said that its drug reduced the risk of hospitalization and death by about 90% in people with mild to moderate infection with the Corona virus, and the company will ask the US Food and Drug Administration and other regulators to approve the drug as soon as possible.

Britain allowed a drug to be taken from Merck earlier this month and is awaiting approval in another country. In a similar deal with the drug-patent pool announced in October, Merck agreed to allow other drug companies to produce COVID-19 pills (molnopiravir) in 105 poor countries.

Pfizer and Merck's decisions to share patents on COVID-19 drugs stand in stark contrast with Pfizer and other vaccine makers refusing to release patents on their vaccines to ensure broader production.

It is reported that less than 1% of doses of the Covid-19 vaccine from Pfizer only went to poor countries.